Open-Label Surufatinib in European Patients With NET
收藏NIAID Data Ecosystem2026-03-12 收录
官方服务：
资源简介：
This is a Phase 2, open-label, multi-centre study of surufatinib in patients with low to intermediate grade (Grade 1 or Grade 2), well-differentiated neuroendocrine tumours (NETs).
创建时间：
2021-08-15
